IgA Nephropathy (IgAN): Clinical Trials

6 trials for IgA Nephropathy (IgAN), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Recruiting 4, Active not recruiting 1, Not yet recruiting 1

Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
JADE101, Placebo - IgA Nephropathy (IgAN)
Phase 3RecruitingJade Biosciences, Inc.4802026-12-012026-11-03
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN)
Phase 3RecruitingNovartis Pharmaceuticals3402026-11-112026-11-19
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
HSK39297, Placebo - IgA Nephropathy (IgAN)
Phase 3RecruitingHaisco Pharmaceutical Group Co., Ltd.3702026-04-072026-05-28
Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
Telitacicept - IgA Nephropathy (IgAN), IgAVN
Phase 3Not yet recruitingGuixia Ding1242025-08-012025-07-10
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
SC0062 strength 10mg, Placebo matched to SC0062 - IgA Nephropathy (IgAN)
Phase 3RecruitingBiocity Biopharmaceutics Co., Ltd.3602025-02-142025-02-17
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN)
Phase 3Active not recruitingThe Affiliated Hospital of Xuzhou Medical University1502024-08-012025-08-01

Narrower conditions

Glomerulonephritis, IGA (6)  ·  Proteinuria (2)  ·  Autoimmune Diseases (1)  ·  Glomerulonephritis (1)  ·  Immune System Diseases (1)  ·  Kidney Diseases (1)  ·  Nephritis (1)  ·  Urogenital Diseases (1)  ·  Urologic Diseases (1)

Broader conditions

Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Male Urogenital Diseases (6)  ·  Autoimmune Diseases (5)  ·  Glomerulonephritis (5)  ·  Immune System Diseases (5)  ·  Kidney Diseases (5)  ·  Nephritis (5)  ·  Urogenital Diseases (5)  ·  Urologic Diseases (5)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)  ·  Urination Disorders (2)  ·  Urological Manifestations (2)

Interventions

telitacicept (2)  ·  Adrenal Cortex Hormones (1)  ·  Angiotensin Receptor Antagonists (1)  ·  Angiotensin-Converting Enzyme Inhibitors (1)  ·  Atrasentan (1)  ·  Methylprednisolone (1)  ·  Prednisolone (1)

Sponsors

Biocity Biopharmaceutics Co., Ltd. (1)  ·  Guixia Ding (1)  ·  Haisco Pharmaceutical Group Co., Ltd. (1)  ·  Jade Biosciences, Inc. (1)  ·  Novartis Pharmaceuticals (1)  ·  The Affiliated Hospital of Xuzhou Medical University (1)

Countries

China (3)  ·  United States (2)  ·  Australia (1)  ·  Israel (1)

Top investigators

Li Li, MD (1)